<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Collateral arteries protect tissue from <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Heart rate correlates with vascular events in patients with <z:e sem="disease" ids="C0003838" disease_type="Disease or Syndrome" abbrv="">arterial obstructive disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we tested the effect of heart-rate reduction (HRR) on collateral artery growth </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: The I(f)-channel inhibitor ivabradine <z:mp ids='MP_0005333'>reduced heart rate</z:mp> by 11% in <z:mp ids='MP_0002169'>wild-type</z:mp> and 15% in <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E (ApoE)(-/-) mice and restored endothelium-dependent relaxation in aortic rings of ApoE(-/-) mice </plain></SENT>
<SENT sid="4" pm="."><plain>Microsphere perfusion and angiographies demonstrated that ivabradine did not change hindlimb perfusion in <z:mp ids='MP_0002169'>wild-type</z:mp> mice but improved perfusion in ApoE(-/-) mice from 40.5 ± 15.8-60.2 ± 18.5% ligated/unligated hindlimb </plain></SENT>
<SENT sid="5" pm="."><plain>Heart rate reduction (13%) with <z:chebi fb="0" ids="6904">metoprolol</z:chebi> failed to improve endothelial function and perfusion </plain></SENT>
<SENT sid="6" pm="."><plain>Protein expression of endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (eNOS), phosphorylated eNOS, and eNOS activity were increased in collateral tissue following ivabradine treatment of ApoE(-/-) mice </plain></SENT>
<SENT sid="7" pm="."><plain>Co-treatment with nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi>-inhibitor N (G)-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> abolished the effects of ivabradine on arteriogenesis </plain></SENT>
<SENT sid="8" pm="."><plain>Following ivabradine, classical inflammatory cytokine expression was lowered in ApoE(-/-) circulating mononuclear cells and in plasma, but unaltered in collateral-containing hindlimb tissue, where numbers of perivascular macrophages also remained unchanged </plain></SENT>
<SENT sid="9" pm="."><plain>However, ivabradine reduced expression of anti-arteriogenic cytokines CXCL10and CXCL11 and of smooth muscle cell markers smoothelin and desmin in ApoE(-/-) hindlimb tissue </plain></SENT>
<SENT sid="10" pm="."><plain>Endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase and inflammatory cytokine expression were unchanged in <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="11" pm="."><plain>Ivabradine did not affect cytokine production in HUVECs and THP1 mononuclear cells and had no effect on the membrane potential of HUVECs in patch-clamp experiments </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Ivabradine-induced HRR stimulates adaptive collateral artery growth </plain></SENT>
<SENT sid="13" pm="."><plain>Important contributing mechanisms include improved endothelial function, eNOS activity, and modulation of inflammatory cytokine gene expression </plain></SENT>
</text></document>